Late Effects in Children and Adolescents with Osteosarcoma

Bielack SS, Hecker-Nolting S, Beck J (2020)

Publication Type: Authored book

Publication year: 2020

Publisher: Springer International Publishing

ISBN: 9783030491406

DOI: 10.1007/978-3-030-49140-6_30

Abstract

Multimodal osteosarcoma therapy according to past and current European and American protocols is described. This includes both local treatment (usually surgery) and systemic antineoplastic therapy, which is often based on high-dose methotrexate, doxorubicin (Adriamycin), cisplatin, and sometimes ifosfamide. As all must be employed at relatively high doses, early and late adverse effects have long been a major research focus. Their long-term late effects on organ function are described, and recommendations for lifelong follow-up are given. These are meant to comply with the evidence-based recommendations of the International Guideline Harmonization Group. Follow-up after surgery of the primary tumor and (endoprosthetic) reconstruction require the expertise of specialized centers.

Authors with CRIS profile

Johannes Beck Lehrstuhl für Psychiatrie und Psychotherapie

Involved external institutions

Klinikum Stuttgart DE Germany (DE)

How to cite

APA:

Bielack, S.S., Hecker-Nolting, S., & Beck, J. (2020). Late Effects in Children and Adolescents with Osteosarcoma. Springer International Publishing.

MLA:

Bielack, Stefan S., Stefanie Hecker-Nolting, and Johannes Beck. Late Effects in Children and Adolescents with Osteosarcoma. Springer International Publishing, 2020.

BibTeX: Download